Group items tagged

Being able to access high-quality healthcare at the times you need it most is vital. Regardless of whether this is a simple check-up, a medical review or complex surgery, having a suitable healthcare package designed according to your medical needs will be beneficial in the long run. The NHS has recently come under significant strain. Factors such as an increase in the number of patients, reduced funding and increased life expectancy have led to long waiting times and limited treatments. As a result, more individuals are now seeking private healthcare which, while it may be more expensive, offers faster and more effective treatment. Here we'll discuss some of the main benefits of private healthcare and why it is becoming the ideal choice for healthcare in 2023. Reduced waiting times One of the main issues faced by the NHS is waiting times, with some patients being made to wait up to a year for routine hospital care. Currently, ambulance services and A&E units are under unprecedented pressure and it is estimated that hundreds of deaths each week are associated with admission delays. Understaffing has been a chronic issue in recent years in the NHS and is a major threat to the welfare of patients. This has been one of the major concerns that has led to nurses and ambulance staff taking strike action. As nurses and hospital workers are put under higher strain, they are more likely to make mistakes, which could well lead to patients coming into harm and making a claim. Opting for private healthcare guarantees that you are able to access your appointments, surgeries and treatments much quicker, with some flexibility offered to align with your lifestyle. The capacity to bypass the painfully long waiting times ensures you receive the necessary medical attention much sooner and could prevent the emergence of other health complications.

The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Dekra to certify medical devices in the UK. Dekra Certification UK has joined the three current UK approved bodies, increasing the UK's capacity to process conformity assessments for medical devices to ensure safe and effective devices reach the UK public. An approved body is an organisation that has been designated by the MHRA to assess whether manufacturers and their medical devices meet the requirements set out in  the UK Medical Devices Regulations 2002. Following an appropriate assessment, the new approved body will issue relevant certification allowing manufacturers to place a UKCA marking on their products before putting them on the market. Dr Laura Squire, chief healthcare quality and access officer at the MHRA, said: "This is a major milestone in our mission to ensure patients across the UK have access to the high-quality medical devices they need to protect their health.

There is a clear opportunity for community pharmacists and their teams to lead best practice when it comes to supporting the ongoing health needs of older people. As the global population continues to age, the demand for specialised healthcare services tailored to the elderly is rapidly increasing. Community pharmacists, with their accessible locations and frequent interactions with patients, are uniquely positioned to play a pivotal role in addressing this growing need. The ageing population presents a complex set of health challenges, including multiple chronic conditions, polypharmacy, and increased susceptibility to adverse drug reactions. Community pharmacists, armed with their extensive knowledge of medications and their effects, can serve as the first line of defence in managing these issues. By leveraging their expertise, they can implement best practices that not only improve the quality of life for older individuals but also reduce the burden on the broader healthcare system. One of the primary areas where community pharmacists can make a significant impact is in medication management. As people age, they often find themselves taking multiple medications for various conditions. This polypharmacy can lead to dangerous drug interactions, side effects, and compliance issues. Community pharmacists can lead the way in implementing comprehensive medication reviews, ensuring that each patient's drug regimen is optimised for their specific needs and minimising potential risks.

A massive global technology outage on Friday has disrupted essential services, including healthcare, airlines, banks, and broadcasters worldwide. The outage, attributed to a flawed update from cybersecurity firm CrowdStrike, has also affected the National Health Service (NHS) in the UK, with several hospitals and GP practices losing access to their computer systems. Community pharmacies are also facing significant disruptions. Services such as accessing prescriptions from GPs and medicine deliveries have been affected, causing inconvenience to patients and healthcare providers. An NHS spokesperson said: "The NHS is aware of a global IT outage and an issue with EMIS, an appointment and patient record system, which is causing disruption in the majority of GP practices." The spokesperson assured that the NHS has long-standing measures in place to manage such disruptions, including the use of paper patient records and handwritten prescriptions, and the usual phone systems to contact GPs.

The Royal Pharmaceutical Society (RPS), professional membership body for pharmacists and pharmacy, has published its manifesto for the general election, highlighting key issues facing the next government after the election on July 4. Local candidates are urged to recognise and support the vital role pharmacists play in supporting people's health. The RPS teams are gearing up to influence government policy in various crucial areas. Their key asks include: Ensuring Secure Patient Access to Medicines Supporting a Better-Connected NHS Enhancing Accessible Prescribing in Local Communities Maximizing Health Improvement through Locally Accessible Pharmacy Teams Supporting the Workforce to Deliver Patient Care Unlocking the Potential of New Advances in Medicines Supporting the UK's Global Position in Science and Research Acknowledging the efforts of pharmacists and their teams, Professor Claire Anderson, President of the RPS, noted that they are "working incredibly hard to maintain patient access to care amid workforce challenges, medicines shortages and financial pressures."

The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity in select countries. This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain. Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company. Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines. Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.

Released on Monday morning, the election manifesto shared by the Liberal Democrats pledges to "strengthen patients' rights" by tackling public health inequalities and providing early access to community services. The Liberal Democrats Party's manifesto promises to address the issues at both the "front and back doors" of the National Health Service (NHS), which the party claims has been plunged into crisis by the Conservatives. Pledging to invest in public health and early access to community services, the party aims to "work towards a fairer and more sustainable long-term funding model for pharmacies and build on the Pharmacy First approach to give patients more accessible routine services and ease the pressure on GPs." The pledge also includes making prescriptions for people with chronic mental health conditions free on the NHS, as part of a wider commitment to review the entire schedule of exemptions for prescription charges.

Following intermittent shortages during the holiday period and amid continued high level of demand for lateral flow tests (LFT) in pharmacies, the industry has voiced concerns over supplies. Royal Pharmaceutical Society in England chair Thorrun Govind recently gave numerous media interviews over the issue, supporting pharmacists and reassuring the public. She said it is 'frustrating' for pharmacy teams who are unable to access enough test kits to meet the growing demand and highlighted that placing all supplies with a single distributor as a key issue. Many in the sector have raised questions about the government's strategy for LFT distribution after it emerged that the sole distributor to pharmacies closed for four days shortly after receiving 2.5 million tests. Alliance Healthcare, from whom pharmacies receive LFTs, reportedly took delivery of the tests on Christmas Eve and then shut.

The English health secretary has fumbled the opportunity to prevent a crisis in the NHS this winter. She either does not understand or value the role of community pharmacy as the third pillar of patient access to essential healthcare. Her announcement that she wants community pharmacy to provide more services to take the strain off A&E departments and GP surgeries comes on the same day DHSC announces no new long-term investment to sustain the sector. Does she not understand that as a result of years of government underinvestment in England the network is in decline with random closures across the country? Too many pharmacies are temporarily closed every day due to workforce shortages beyond the control of pharmacy owners. Adding a new service here and there, even with some additional funding, does not address the longer term viability of the network which needs to know which patient services it will be expected to provide over the next 10 years - not just the next few months - and how those will be adequately remunerated. Asking more from our sector with no new investment is a strategy which is bound to fail. The pharmacy contract remains economically illiterate. The sector's finances need open heart surgery not a couple of paracetamol tablets.

Poverty not only takes a significant toll on people's health but also leads to additional costs for the National Health Service (NHS). Rise in deep poverty, cost-of-living crisis, and high pressure on NHS services have worsened the situation, according to a study published by The King's Fund this week. The report underscored that poverty and deprivation contribute to a greater prevalence of diseases, difficulties in accessing health care, late or delayed treatment, and worse health outcomes. These challenges could be seen across various NHS services, spanning from emergency care to dental services Additionally, it revealed that 30 per cent of people living in the most deprived areas have turned to 999, 111, A&E or a walk-in centre because they could not access a GP appointment. In 2016, the Joseph Rowntree Foundation (JRF) estimated the cost of poverty on health care at £29 billion (£34 billion in current prices). As the proportion of people living in deep poverty has risen, the situation has worsened. In 2021/22, six million people were living in very deep poverty, up from 4.5 million two decades ago. Currently, more than one in five people in the UK are estimated to be living in poverty, the report noted. Deprivation is linked to a range of diet-related health problems, including cardiovascular disease and diabetes, as well as mental illness. According to the report, the depression rate is two times higher among people living in the most deprived areas, compared to the least deprived areas.

"It is crucial that patients can access care when they need it, whether from a pharmacist or a GP, " Paul Rees, Chief Executive of the National Pharmacy Association (NPA) has said. In response to a recent survey conducted by the General Medical Council (GMC) highlighting alarming trends among General Practitioners (GPs), the NPA has issued a warning about the growing crisis in the UK's primary care system. Rees emphasised the urgent need for government intervention, saying, "Only by reversing these cuts and providing pharmacies with a new funding deal will we be able to end the 8am scramble for appointments." The GMC survey reveals that there is a significant increase in the number of doctors reducing their working hours to safeguard their wellbeing, spotlighting concerns about the long-term impact on patient care. According to the report, nearly half of GPs ( 48 per cent) are struggling to manage their workload, with several resorting to decreasing their hours or declining additional work to protect their mental and physical health.

The General Pharmaceutical Council (GPhC) has urged health and care professionals to meet relevant regulatory standards amidst the shortage of GLP-1 receptor agonists (GLP-1 RAs). The council said: "We are concerned to hear that people with Type 2 diabetes are experiencing problems accessing GLP-1 receptor agonists (GLP-1 RAs). We know that these are being widely prescribed for weight loss purposes and in some cases prescribed off-label." "We recognise the adverse impact that shortages and supply chain issues can have on patients, the public and wider health and care teams. The Council understands that health and care professionals are using their professional judgement and making decisions in challenging situations, balancing a range of factors such as individual patient needs, wider public health and pressures and limitations on available resources such as medicines shortages or other supply chain issues.

Sobha Sharma Kandel wants community pharmacy teams up and down the country to be super responsive to emerging needs of their patients - by always being pro-active rather than reactive. "We know that every patient benefits from our proactive approaches - listening, asking questions, providing information and making clinical interventions when appropriate. "At a time when general practice is overstretched, community pharmacy must be relied upon as the frontline of the NHS when it comes to providing diagnosis, treatment and continuous care in our communities to promote health and wellbeing of our patients." Sobha believes Covid-19 has helped shift public perception of community pharmacies from being a place where one goes to collect a prescription to a hub where one can access a range of healthcare advice and services. "We are way more than just a shop where you can collect your medicines," she said, giving examples of how her interventions have helped reduce medication errors, prevent harm and subsequently reduce cost of care. She once saved a baby from getting overdosed with omeprazole when they had issues with gastroesophageal reflux. On another occasion, she managed a lady's high blood pressure by finding equivalent medications to a combination dose prescribed by her doctor in another country.

The Department of Health and Social Care (DHSC) published a notification regarding the shortage of Guanfacine 2mg and 3mg modified-release tablets has raised concerns within the healthcare community. This critical medicine supply notification, issued on March 28th, projects the unavailability of these tablets until the week commencing May 6, 2024. Guanfacine tablets, commonly prescribed to alleviate symptoms of hyperactivity and impulsivity while enhancing attention and concentration, play a vital role in managing conditions like attention deficit hyperactivity disorder (ADHD). However, the scarcity of these specific strengths poses challenges for patients reliant on this medication. Last year, several countries across the globe experienced shortages of medications for the treatment of attention deficit hyperactivity disorder (ADHD)including the UK, the US and Australia. Community Pharmacy England (CPE) has cautioned that while alternative strengths of Guanfacine remain accessible, they may not adequately meet the heightened demand, potentially resulting in treatment interruptions for patients.

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.